Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial
Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.
Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.